Last checked at 4 Sep 2009 07:00
| For immediate release | 4 SEPTEMBER 2009 |
OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
Oxford, UK - 4 September 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that John Dawson, its Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference to be held on 9-11 September at the New York Palace Hotel in New York City. The presentation is scheduled on Thursday, 10 September at 2.50pm ET (7.50pm BST).
-Ends-
| For further information, please contact: | |
| Oxford BioMedica plc: John Dawson, Chief Executive Officer Nick Woolf, Chief Business Officer | Tel: +44 (0)1865 783 000 |
| JPMorgan Cazenove Limited: James Mitford/ Gina Gibson | Tel: +44 (0)20 7588 2828 |
| Media/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Elliott Buchanan Communications | Tel: +44 (0)20 7466 5000 |
| US Enquiries: Thomas Fechtner The Trout Group LLC | Tel: (646) 378 2900 |
Notes to editors
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk